2121 related articles for article (PubMed ID: 32929370)
1. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
2. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
3. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
4. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
5. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Kumar A; Ramani V; Bharti V; de Lima Bellan D; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM; Vilgelm A
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230537
[TBL] [Abstract][Full Text] [Related]
8. The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Schaer DA; Beckmann RP; Dempsey JA; Huber L; Forest A; Amaladas N; Li Y; Wang YC; Rasmussen ER; Chin D; Capen A; Carpenito C; Staschke KA; Chung LA; Litchfield LM; Merzoug FF; Gong X; Iversen PW; Buchanan S; de Dios A; Novosiadly RD; Kalos M
Cell Rep; 2018 Mar; 22(11):2978-2994. PubMed ID: 29539425
[TBL] [Abstract][Full Text] [Related]
9. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
10. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
11. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
12. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis.
Nayyar N; de Sauvage MA; Chuprin J; Sullivan EM; Singh M; Torrini C; Zhang BS; Bandyopadhyay S; Daniels KA; Alvarez-Breckenridge C; Dahal A; Brehm MA; Brastianos PK
Clin Cancer Res; 2024 Jan; 30(2):420-435. PubMed ID: 37611074
[TBL] [Abstract][Full Text] [Related]
14. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
15. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
16. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
Du B; Wen X; Wang Y; Lin M; Lai J
Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
[TBL] [Abstract][Full Text] [Related]
18. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
[TBL] [Abstract][Full Text] [Related]
19. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
[TBL] [Abstract][Full Text] [Related]
20. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
Teh JLF; Aplin AE
Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
